Document is current
Any future updates will be listed below
-
Authors
Mucci, Adele https://orcid.org/0000-0003-1532-4414
Antonarelli, Gabriele
Caserta, Carolina
Vittoria, Francesco Maria
Desantis, Giacomo https://orcid.org/0000-0002-7158-2218
Pagani, Riccardo https://orcid.org/0000-0003-4109-5395
Greco, Beatrice
Casucci, Monica
Escobar, Giulia
Passerini, Laura
Lachmann, Nico
Sanvito, Francesca
Barcella, Matteo
Merelli, Ivan
Naldini, Luigi https://orcid.org/0000-0002-7835-527X
Gentner, Bernhard https://orcid.org/0000-0001-6024-4718
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (AIRC‐IG 2018 Id.22143)
Fondazione Telethon (Telethon Core Grant 2016/C1)
Fondazione Umberto Veronesi
- License Information
-
More Information
Article History
Received: 16 October 2020
Revised: 11 August 2021
Accepted: 12 August 2021
First Online: 30 August 2021
Conflict of interest
: B.Ge. is a founder of Genenta Science, a biotech start‐up financing the clinical development of IFN‐α gene therapy. Genenta did not fund the research on IFN‐γ gene therapy presented in this manuscript, nor does Genenta have ownership rights on the data presented herein.
